Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73633347" target="_blank" >RIV/61989592:15110/25:73633347 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S2152265025042697?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2152265025042697?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clml.2025.10.022" target="_blank" >10.1016/j.clml.2025.10.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

Popis výsledku v původním jazyce

A 17-year real-world analysis of 2,281 transplant-ineligible newly diagnosed multiple myeloma patients treatedwith bortezomib-based triplets showed superior response, PFS and OS with VRD compared with VMP, CVDand VTD, despite higher toxicity. In frail or elderly subgroups, regimen differences diminished. VRD representsthe most effective option where anti-CD38 therapies are not accessible.Background: Multiple myeloma (MM) is a hematologic malignancy defined by clonal proliferation of plasma cells inthe bone marrow. The introduction of bortezomib, a proteasome inhibitor, has significantly improved outcomes in MM,becoming a cornerstone of therapy since its approvals for relapsed/refractory MM in 2003 and newly diagnosed MM(NDMM) in 2008. Bortezomib induces apoptosis in malignant plasma cells by disrupting protein degradation pathways.Rationale: Triplet regimens combining bortezomib with immunomodulatory drugs, alkylating agents, and corticosteroidshave shown high efficacy, especially in NDMM patients ineligible for autologous stem cell transplant (ASCT). However,clinical trials often underrepresent real-world populations, with 40% to 50% of MM patients not meeting eligibility criteria. Methods: To address this evidence gap, we performed a retrospective analysis of national real-world data fromthe Czech Republic, assessing 17 years of experience with bortezomib-based triplet regimens in transplant-ineligibleNDMM patients. Conclusions: This study provides critical insights into the long-term effectiveness and applicability

Název v anglickém jazyce

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

Popis výsledku anglicky

A 17-year real-world analysis of 2,281 transplant-ineligible newly diagnosed multiple myeloma patients treatedwith bortezomib-based triplets showed superior response, PFS and OS with VRD compared with VMP, CVDand VTD, despite higher toxicity. In frail or elderly subgroups, regimen differences diminished. VRD representsthe most effective option where anti-CD38 therapies are not accessible.Background: Multiple myeloma (MM) is a hematologic malignancy defined by clonal proliferation of plasma cells inthe bone marrow. The introduction of bortezomib, a proteasome inhibitor, has significantly improved outcomes in MM,becoming a cornerstone of therapy since its approvals for relapsed/refractory MM in 2003 and newly diagnosed MM(NDMM) in 2008. Bortezomib induces apoptosis in malignant plasma cells by disrupting protein degradation pathways.Rationale: Triplet regimens combining bortezomib with immunomodulatory drugs, alkylating agents, and corticosteroidshave shown high efficacy, especially in NDMM patients ineligible for autologous stem cell transplant (ASCT). However,clinical trials often underrepresent real-world populations, with 40% to 50% of MM patients not meeting eligibility criteria. Methods: To address this evidence gap, we performed a retrospective analysis of national real-world data fromthe Czech Republic, assessing 17 years of experience with bortezomib-based triplet regimens in transplant-ineligibleNDMM patients. Conclusions: This study provides critical insights into the long-term effectiveness and applicability

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lymphoma Myeloma &amp; Leukemia

ISSN

2152-2650

e-ISSN

2152-2669

Svazek periodika

26

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

"e470"-"e482"

Kód UT WoS článku

001736055900001

EID výsledku v databázi Scopus

2-s2.0-105023889294